Harvard Bioscience (NASDAQ:HBIO - Get Free Report) is scheduled to issue its quarterly earnings data on Tuesday, April 23rd.
Harvard Bioscience (NASDAQ:HBIO - Get Free Report) last issued its earnings results on Thursday, March 7th. The medical instruments supplier reported $0.01 EPS for the quarter, missing the consensus estimate of $0.03 by ($0.02). The firm had revenue of $28.15 million during the quarter, compared to analysts' expectations of $27.80 million. Harvard Bioscience had a positive return on equity of 2.75% and a negative net margin of 3.04%.
Harvard Bioscience Price Performance
HBIO remained flat at $3.70 during trading on Monday. 90,516 shares of the company's stock traded hands, compared to its average volume of 85,504. The company has a market cap of $160.58 million, a price-to-earnings ratio of -46.24 and a beta of 1.42. Harvard Bioscience has a fifty-two week low of $3.60 and a fifty-two week high of $6.29. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.85 and a quick ratio of 0.92. The company has a 50-day moving average price of $4.30 and a 200-day moving average price of $4.49.
About Harvard Bioscience
(
Get Free Report)
Harvard Bioscience, Inc develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings.
Featured Stories
Before you consider Harvard Bioscience, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Harvard Bioscience wasn't on the list.
While Harvard Bioscience currently has a "hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
